There is no single best biologic for Crohn’s disease. The right choice depends on your disease location, whether you have fistulas, how you’ve responded to previous treatments, and what side effects matter most to you. That said, recent head-to-head trials are starting to separate the options in ways that weren’t possible even a few years ago, and the newest class of biologics, IL-23 inhibitors, is showing particularly strong results.
The Four Classes of Biologics
Biologics for Crohn’s fall into four broad categories, each targeting a different part of the immune system. Anti-TNF drugs were the first biologics approved for Crohn’s and remain the most widely used. They block a protein called tumor necrosis factor that drives inflammation throughout the body. The two main options in this class are infliximab (given by IV infusion) and adalimumab (a self-injection).
The second class targets a protein involved in routing immune cells to the gut. Vedolizumab works exclusively in the digestive tract rather than suppressing the immune system body-wide. This gut-selective approach means it doesn’t interfere with immune surveillance in the brain or other organs, which gives it a favorable safety profile compared to drugs that act systemically.
The third class, represented by ustekinumab, blocks two immune signaling molecules (IL-12 and IL-23) that help activate inflammatory cells. The newest and fourth class, which includes risankizumab and guselkumab, targets only IL-23. This narrower approach appears to deliver better gut healing with fewer off-target effects.
What the Head-to-Head Data Shows
Most biologic trials compare a drug to a placebo, which makes it hard to say whether one biologic actually outperforms another. The SEQUENCE trial changed that by directly comparing risankizumab to ustekinumab in patients with moderate-to-severe Crohn’s who had already failed or couldn’t tolerate anti-TNF therapy.
The results were clear. At 24 weeks, 58.6% of patients on risankizumab achieved clinical remission compared to 39.5% on ustekinumab. More importantly, at 48 weeks risankizumab was statistically superior for endoscopic remission, meaning actual healing of the intestinal lining visible on colonoscopy: 31.8% versus 16.2%. Endoscopic healing matters because it predicts long-term outcomes better than symptom improvement alone. These results have positioned risankizumab as a leading option for patients who need to move beyond anti-TNF therapy.
When Anti-TNF Drugs Are Still the First Choice
Despite the strong performance of newer biologics, anti-TNF agents remain the most appropriate starting point in several scenarios. If you have fistulizing Crohn’s, where abnormal tunnels form between the intestine and other structures, anti-TNF drugs have the most evidence behind them. They’re also preferred when Crohn’s is accompanied by extraintestinal manifestations like joint inflammation, certain skin conditions, or eye problems, which affect roughly half of people with inflammatory bowel disease.
Anti-TNF drugs also work fast. Infliximab can produce a clinical response within 8 to 9 days, and about 81% of patients in trials responded by week 4. Adalimumab shows remission rates around 36% by week 4. For patients who need rapid relief, particularly those who are malnourished or facing surgery, that speed matters.
Results tend to be strongest in patients whose disease is inflammatory rather than stricturing. When Crohn’s has already caused significant narrowing or scarring of the intestine, biologics of any class are less effective because scar tissue doesn’t respond to immune suppression.
How Quickly Each Class Works
The timeline for feeling better varies meaningfully between biologic classes. Anti-TNF drugs are the fastest, with most patients seeing a response within the first two months and many improving within days of the first infusion.
Vedolizumab is slower. Clinical remission takes at least 10 to 14 weeks in Crohn’s, and in one study the median time to response was 19 weeks. Its gut-selective mechanism means it needs time to interrupt the cycle of immune cells migrating to the intestinal lining. If you’re starting vedolizumab, plan for a longer ramp-up period before judging whether it’s working.
IL-23 inhibitors like risankizumab fall somewhere in between. In the head-to-head trial against ustekinumab, meaningful separation in remission rates was already apparent at 24 weeks, with continued improvement through 48 weeks.
Safety Differences Between Classes
A large meta-analysis of 49 placebo-controlled trials involving over 14,500 patients found that biologics as a class moderately increase the risk of common infections (colds, upper respiratory infections) and roughly double the risk of opportunistic infections. However, they did not increase the risk of serious infections requiring hospitalization. In fact, among the highest-quality studies, biologics actually reduced serious infection risk, likely because controlling intestinal inflammation improves overall health.
The risk of cancer, a common concern, was not increased with biologic use in the available data, though long-term follow-up remains limited.
Where the classes differ is in the type of immune suppression. Anti-TNF drugs suppress the immune system broadly, which is why they can treat joint and skin problems but also carry a slightly higher infection burden. Vedolizumab’s gut-selective action avoids this tradeoff. It doesn’t suppress immune function in the brain or lungs, which is why it has not been linked to the rare but serious brain infection (progressive multifocal leukoencephalopathy) that was seen with an older, less targeted gut drug called natalizumab. IL-23 inhibitors also appear to have a clean safety profile, though they haven’t been on the market as long.
Losing Response Over Time
One of the biggest challenges with biologics is secondary loss of response, where a drug that initially worked gradually stops controlling symptoms. This happens most commonly with anti-TNF drugs and is often caused by the body developing antibodies against the medication, which neutralize it or speed its clearance from the bloodstream.
When this happens, doctors can increase the dose or shorten the interval between doses. Research shows that what matters most isn’t your drug level at the time symptoms return, but whether dose adjustment successfully raises your drug level afterward. In one multicenter study, patients who achieved higher drug levels after dose escalation were significantly more likely to regain remission at 6 and 12 months, regardless of where their levels started.
Newer biologic classes, particularly IL-23 inhibitors, appear to have lower rates of antibody formation, which is one reason they’re gaining favor as both first-line and second-line options.
Biosimilars Are Equivalent
If your doctor prescribes infliximab or adalimumab, you may receive a biosimilar, a near-identical copy of the original drug made by a different manufacturer at lower cost. A systematic review of switching studies found no clinically important differences in efficacy, safety, or immune reactions between biosimilars and their reference products. If your insurance or pharmacy switches you to a biosimilar, the evidence supports that your outcomes should be the same.
Choosing the Right Biologic for You
The decision comes down to a few practical questions. If you have fistulas or significant extraintestinal symptoms, anti-TNF drugs have the strongest track record. If you’ve already tried an anti-TNF drug and it failed or caused side effects, risankizumab now has the best head-to-head evidence in that population. If safety is your top priority and your disease is not urgent, vedolizumab’s gut-selective mechanism offers the gentlest immune impact, though you’ll wait longer for it to kick in.
Your disease behavior also matters. Inflammatory disease without stricturing or penetrating complications responds best to biologics overall. If your Crohn’s has already caused significant scar tissue, no biologic will reverse that, and you may need a combined approach involving surgery or endoscopic treatment alongside medication. The “best” biologic is ultimately the one that matches your specific disease pattern, your treatment history, and the timeline your body can afford to wait.